Supportive Care in Cancer

, Volume 26, Issue 5, pp 1607–1615 | Cite as

Chemotherapy-related neuropathic symptom management: a randomized trial of an automated symptom-monitoring system paired with nurse practitioner follow-up

  • Noah Allan Kolb
  • Albert Gordon Smith
  • John Robinson Singleton
  • Susan L. Beck
  • Diantha Howard
  • Kim Dittus
  • Summer Karafiath
  • Kathi Mooney
Original Article
First Online:
Received:
Accepted:

Abstract

Purpose

The purpose of this study was to evaluate a new care model to reduce chemotherapy-induced neuropathic symptoms. Neuropathic symptom usual care was prospectively compared to an automated symptom-monitoring and coaching system, SymptomCare@Home (SCH), which included nurse practitioner follow-up triggered by moderate to severe symptoms.

Methods

Patients beginning chemotherapy were randomized to usual care (UC) or to the SCH intervention. This sub-analysis included only taxane/platin therapies. Participants called the automated telephone symptom-monitoring system daily to report numbness and tingling. The monitoring system recorded patient-reported neuropathic symptom severity, distress, and activity interference on a 0–10 scale. UC participants were instructed to call their oncologist for symptom management. SCH participants with symptom severity of ≥ 4 received automated self-care strategies, and a nurse practitioner (NP) provided guideline-based care.

Results

There were 252 participants, 78.6% of which were female. Mean age was 55.1 years. Mean follow-up was 90.2 ± 39.9 days (81.1 ± 40.3 calls). SCH participants had fewer days of moderate (1.8 ± 4.0 vs. 8.6 ± 17.3, p < 0.001) and severe chemotherapy-induced peripheral neuropathy symptoms (0.3 ± 1.0 vs. 1.1 ± 5.2, p = 0.006). SCH participants had fewer days with moderate and severe symptom-related distress (1.4 ± 3.7 vs. 6.9 ± 15.0, p < 0.001; 0.2 ± 0.9 vs. 1.5 ± 6.1, p = 0.001) and trended towards less activity interference (3.3 ± 1.9 vs. 3.8 ± 2.1, p = 0.08). Other neuropathic symptoms were addressed in 5.8–15.4% of SCH follow-up calls.

Conclusions

The SCH system effectively identified neuropathic symptoms and their severity and, paired with NP follow-up, reduced symptom prevalence, severity, and distress compared to usual care.

Keywords

Chemotherapy Neuropathy Neuropathic pain Supportive care Nurse practitioner Cancer Telemedicine 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgements

Noah Kolb, MD’s, research time was supported by the National Institute of Health KL2TR001065.

Author contributions

N. Kolb, MD; A.G. Smith, MD; J. R. Singleton, MD; S. L. Beck, PhD, APRN, FAAN, AOCN; D. Howard, MS, MA; K. Dittus, MD, PhD; S. Brown, MD; and K Mooney, PhD, RN, FAAN all affirm responsibility for the following content:

1. Substantial contributions to the conception and design or acquisition of data or analysis and interpretation of the data

2. Drafting the article or revising it critically for important intellectual content

3. Approval of the version to be published and all subsequent versions

Funding information

The study was sponsored by the National Institute of Health R01 CA120558 (KM).

Compliance with ethical standards

The IRB at the University of Utah and Vanderbilt approved the study protocol. All participants signed a written informed consent prior to enrollment and randomization.

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

The IRB at the University of Utah and Vanderbilt approved the study protocol. All participants signed a written informed consent prior to enrollment and randomization.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Tofthagen C, Donovan KA, Morgan MA, Shibata D, Yeh Y (2013) Oxaliplatin-induced peripheral neuropathy’s effects on health-related quality of life of colorectal cancer survivors. Support Care Cancer : Off J Multinatl Assoc Support Care Cancer 1Google Scholar
  2. 2.
    Mols F, Beijers T, Lemmens V, van den Hurk CJ, Vreugdenhil G, van de Poll-Franse LV (2013) Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol : Off J Am Soc Clin Oncol 31(21):2699–2707.  https://doi.org/10.1200/JCO.2013.49.1514 CrossRefGoogle Scholar
  3. 3.
    Argyriou AA, Bruna J, Marmiroli P, Cavaletti G (2012) Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol 82(1):51–77.  https://doi.org/10.1016/j.critrevonc.2011.04.012 CrossRefPubMedGoogle Scholar
  4. 4.
    Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN, Kamal A, Le-Lindqwister NA, Soori GS, Jaslowski AJ, Kelaghan J, Novotny PJ, Lachance DH, Loprinzi CL (2012) Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy: North Central Cancer Treatment Group trial N08C1. Cancer 118(20):5171–5178.  https://doi.org/10.1002/cncr.27489 CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Argyriou AA, Cavaletti G, Briani C, Velasco R, Bruna J, Campagnolo M, Alberti P, Bergamo F, Cortinovis D, Cazzaniga M, Santos C, Papadimitriou K, Kalofonos HP (2012) Clinical pattern and associations of oxaliplatin acute neurotoxicity. Cancer 119(2):438–444.  https://doi.org/10.1002/cncr.27732 CrossRefPubMedGoogle Scholar
  6. 6.
    Kolb NA, Smith AG, Singleton JR, Beck SL, Stoddard GJ, Brown S, Mooney K (2016) The association of chemotherapy-induced peripheral neuropathy symptoms and the risk of falling. JAMA Neurol 73(7):860–866.  https://doi.org/10.1001/jamaneurol.2016.0383 CrossRefPubMedGoogle Scholar
  7. 7.
    Tofthagen C, Overcash J, Kip K (2011) Falls in persons with chemotherapy-induced peripheral neuropathy. Support Care Cancer : Off J Multinatl Assoc Support Care Cancer [Internet] 20(3):583–589. Available from: http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=21380613&retmode=ref&cmd=prlinks.  https://doi.org/10.1007/s00520-011-1127-7 CrossRefGoogle Scholar
  8. 8.
    Ward PR, Wong MD, Moore R, Naeim A (2014) Fall-related injuries in elderly cancer patients treated with neurotoxic chemotherapy: a retrospective cohort study. J Geriatr Oncol 5(1):57–64.  https://doi.org/10.1016/j.jgo.2013.10.002 CrossRefPubMedGoogle Scholar
  9. 9.
    Speck RM, Sammel MD, Farrar JT, Hennessy S, Mao JJ, Stineman MG, DeMichele A (2013) Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer. J Oncol Pract Am Soc Clin Oncol [Internet] 9(5):e234–e240. Available from: http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=23943894&retmode=ref&cmd=prlinks.  https://doi.org/10.1200/JOP.2012.000863 CrossRefGoogle Scholar
  10. 10.
    Beck SL, Eaton LH, Echeverria C, Mooney KH SymptomCare@home: developing an integrated symptom monitoring and management system for outpatients receiving chemotherapy. Comput Inform NursGoogle Scholar
  11. 11.
    Mooney KH, Beck SL, Wong B, Dunson W, Wujcik D, Whisenant M, et al (2017) Automated home monitoring and management of patient-reported symptoms during chemotherapy: results of the symptom care at home RCT. Cancer Med 30Google Scholar
  12. 12.
    Mooney KH, Beck SL, Friedman RH, Farzanfar R (2002) Telephone-linked care for cancer symptom monitoring: a pilot study. Cancer Pract 10(3):147–154.  https://doi.org/10.1046/j.1523-5394.2002.103006.x CrossRefPubMedGoogle Scholar
  13. 13.
    Cleeland CS, Fisch MJ (2010) Dunn AJ. Cambridge University Press, Cancer symptom scienceGoogle Scholar
  14. 14.
    Tofthagen C (2010) Surviving chemotherapy for colon cancer and living with the consequences. J Palliat Med 13(11):1389–1391.  https://doi.org/10.1089/jpm.2010.0124 CrossRefPubMedGoogle Scholar
  15. 15.
    Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino A, Lustberg MB, Paice J, Schneider B, Smith ML, Smith T, Terstriep S, Wagner-Johnston N, Bak K, Loprinzi CL, American Society of Clinical Oncology (2014) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol : Off J Am Soc Clin Oncol 32(18):1941–1967.  https://doi.org/10.1200/JCO.2013.54.0914 CrossRefGoogle Scholar
  16. 16.
    Cancer patients fear chemotherapy as much as mortality. Free Online Library [Internet]. thefreelibrary.com. [cited 2016 Dec 6]. Available from: https://www.thefreelibrary.com/Cancer+Patients+Fear+Chemotherapy+as+Much+as+Mortality.-a054491359
  17. 17.
    Dodd MJ, Mood DW (1981) Chemotherapy: helping patients to know the drugs they are receiving and their possible side effects. Cancer Nurs 4(4):311–318.  https://doi.org/10.1097/00002820-198108000-00007 CrossRefPubMedGoogle Scholar
  18. 18.
    Dodd MJ (1988) Efficacy of proactive information on self-care in chemotherapy patients. Patient Educ Couns 11(3):215–225.  https://doi.org/10.1016/0738-3991(88)90021-3 CrossRefPubMedGoogle Scholar
  19. 19.
    Dodd MJ, Dibble SL, Thomas ML (1992) Outpatient chemotherapy: patients “ and family members” concerns and coping strategies. Public Health Nurs 9(1):37–44.  https://doi.org/10.1111/j.1525-1446.1992.tb00070.x CrossRefPubMedGoogle Scholar
  20. 20.
    Friedman RH, Kazis LE, Jette A, Smith MB, Stollerman J, Torgerson J et al (1996) A telecommunications system for monitoring and counseling patients with hypertension. Impact on medication adherence and blood pressure control. Am J Hypertens 9(4 Pt 1):285–292.  https://doi.org/10.1016/0895-7061(95)00353-3 CrossRefPubMedGoogle Scholar
  21. 21.
    Collins R, Peto R, MacMahon S, Godwin J, Qizilbash N (1990) Blood pressure, stroke, and coronary heart disease: part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 335(8693):827–838.  https://doi.org/10.1016/0140-6736(90)90944-Z CrossRefPubMedGoogle Scholar
  22. 22.
    Majithia N, Loprinzi CL, Smith TJ. New practical approaches to chemotherapy-induced neuropathic pain: prevention, assessment, and treatment. Oncology (Williston Park, NY). 2016 Nov 15;30(11)Google Scholar
  23. 23.
    Gewandter JS, Fan L, Magnuson A, Mustian K, Peppone L, Heckler C, Hopkins J, Tejani M, Morrow GR, Mohile SG (2013) Falls and functional impairments in cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study. Support Care Cancer : Off J Multinatl Assoc Support Care Cancer 21(7):2059–2066.  https://doi.org/10.1007/s00520-013-1766-y CrossRefGoogle Scholar
  24. 24.
    Stone CA, Lawlor PG, Kenny RA (2011) How to identify patients with cancer at risk of falling: a review of the evidence. J Palliat Med [Internet] 14(2):221–230. Available from: http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=21214370&retmode=ref&cmd=prlinks.  https://doi.org/10.1089/jpm.2010.0326 CrossRefGoogle Scholar
  25. 25.
    Rutledge D, McGuire C (2004) In: Yarbro CH, Frogge MM, Goodman M (eds) Evidence-based symptom management. Jones and Bartlett, SundburyGoogle Scholar
  26. 26.
    Kotronoulas G, Kearney N, Maguire R, Harrow A, Di Domenico D, Croy S et al (2014) What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care? A systematic review of controlled trials. J Clin Oncol : Off J Am Soc Clin Oncol. Am Soc Clin Oncol 32(14):1480–1501CrossRefGoogle Scholar
  27. 27.
    Basch E, Deal AM, Dueck AC, Scher HI, Kris MG, Hudis C, Schrag D (2017) Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA Am Med Assoc 318(2):197–198.  https://doi.org/10.1001/jama.2017.7156 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2017

Authors and Affiliations

  1. 1.Department of NeuroscienceUniversity of Vermont Medical CenterBurlingtonUSA
  2. 2.Department of NeurologyUniversity of UtahSalt Lake CityUSA
  3. 3.College of NursingUniversity of UtahSalt Lake CityUSA
  4. 4.Huntsman Cancer InstituteSalt Lake CityUSA
  5. 5.Clinical Research CenterUniversity of VermontBurlingtonUSA
  6. 6.Department of Medicine, Hematology/OncologyUniversity of VermontBurlingtonUSA

Personalised recommendations